Ecopipam as a pharmacologic treatment of stuttering.
Gerald A Maguire, Lisa LaSalle, Debra Hoffmeyer...
https://pubmed.ncbi.nlm.nih.gov/31369655/Actively Recruiting
Led by CSTrials Inc. · Updated on 2026-07-29
24
Participants Needed
1
Research Sites
13 weeks
Total Duration
Researchers are evaluating Lumateperone as a treatment for adults with developmental stuttering, also known as childhood-onset fluency disorder. This double-blind, placebo-controlled Phase 2 trial focuses on adults aged 18 to 65 with moderate to severe stuttering symptoms. The study aims to assess both the effectiveness and tolerability of Lumateperone in reducing stuttering. Participants will be randomly assigned to receive either Lumateperone tablets, taken once daily with flexible dosing from 21 mg up to 42 mg, or a matching placebo. The trial uses a parallel design and includes multiple outcome assessments such as the Maguire-Leal-Garibaldi Self-Rated Stuttering Scale MLGSSS, Clinical Global Impression scales, and other measures of stuttering severity and side effects. The study is planned to enroll 24 subjects, with screening of about 30 to find suitable candidates. During the study, participants will undergo thorough clinical screening and provide written consent before enrollment. Researchers will collect various clinical scales and samples, including stuttering severity instruments and assessments for psychiatric and movement-related side effects. The primary outcomes include changes in stuttering severity and global impression of symptoms over the past week. The total study period extends until late 2027, with ongoing monitoring of efficacy and safety throughout the trial.
CONDITIONS
Lumateperone in the Treatment of Stuttering, Childhood Onset Fluency Disorder
T
Tommy Gonzalez, MA
D
Debra Hoffmeyer, MA
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
CSTrials Inc.
Lead Sponsor
This table compares participation in this trial with other options available for this condition. The information is drawn from published research and the trial’s study details and is provided for educational purposes only.
| Factors | Lumateperone (daily tablet, investigational) | Placebo (matching tablet) |
|---|---|---|
| What it is | An investigational oral drug (lumateperone; ITI-007) taken as a tablet once daily, being studied for possible benefit in adults with childhood-onset stuttering. | A tablet or capsule that contains no active drug (placebo), matched in appearance to the study drug, taken once daily. |
| Role in trial | Active investigational treatment arm; assesses the effect of daily lumateperone compared to placebo. | Placebo control arm; serves as the comparison group for evaluating lumateperone. |
| Primary use | Being evaluated for the reduction of stuttering symptoms (fluency disorder) in adults with childhood-onset stuttering. | Serves as a no-active-treatment control to distinguish true drug benefit from placebo effect on stuttering symptoms. |
| How it is given | Tablet is taken orally once daily. Dose may range between 21mg and up to 42mg. | Oral placebo tablet or capsule is taken once daily, matching the appearance of the investigational drug. |
| Evidence status | Efficacy in reducing stuttering symptoms remains under clinical investigation and is not yet established. Other pharmacologic treatments such as ecopipam, risperidone, and lurasidone have been explored for stuttering in previous research, but no medication is currently approved specifically for this use. | Placebo does not contain an active medication; provides a baseline to distinguish treatment effect from expectation or background improvement. |
| Important limitations | As an ongoing investigational trial, results for lumateperone are not yet established. Sample size is limited and only adults who speak English are eligible. There is no active comparator arm with another medication, so direct head-to-head efficacy or safety comparisons with other drug therapies for stuttering remain untested within this trial. | Placebo groups do not provide information about effectiveness or safety compared with other available drug options, and do not reflect standard clinical management outside research. |
Disclaimer: This comparison is created with the help of artificial intelligence(AI) and may contain errors or missing information. It is not medical advice and does not mean one option is better or safer than another. Clinical trials are still being studied, and joining a trial is your choice. Please consult your healthcare professional before making any decisions.
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Duration - Up to the completion of the study in 2027
Participants receive either Lumateperone tablets or a matching placebo once daily with flexible dosing.
Regular visits for assessments
Study Type
INTERVENTIONAL
Masking
QUADRUPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Gerald A Maguire, Lisa LaSalle, Debra Hoffmeyer...
https://pubmed.ncbi.nlm.nih.gov/31369655/Gerald A Maguire, Bo Ram Yoo, Shahriar SheikhBahaei
https://pubmed.ncbi.nlm.nih.gov/33642973/Janet Charoensook, Gerald A Maguire
https://pubmed.ncbi.nlm.nih.gov/28738099/CSTrials Inc.
Lead Sponsor